TYK2 signaling dependency in CALR/MPL-mutant MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-24 — Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.: Preclinical study with structural, cellular, primary-sample, and iPSC evidence establishes that CALR- and MPL-mutant MPNs selectively depend on TYK2 signaling (with JAK2 displacing TYK2 from TPOR in JAK2V617F disease, making that context TYK2-independent), and shows deucravacitinib—alone or with fedratinib—suppresses mutant clones and ET/PMF colony growth while sparing JAK2V617F-driven disease. (novelty: 5)